These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 19719456)

  • 1. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.
    Sharifi N
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1046-51. PubMed ID: 19719456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
    Kim W; Jones JO; Diamond M; Haqq C; Molina A; Small EJ; Ryan CJ
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):292-9. PubMed ID: 25047002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
    Kageyama Y; Hyochi N; Kihara K; Sugiyama H
    Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
    Attard G; Richards J; de Bono JS
    Clin Cancer Res; 2011 Apr; 17(7):1649-57. PubMed ID: 21372223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
    Merseburger AS; Hupe MC
    Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal Therapy for Prostate Cancer.
    Desai K; McManus JM; Sharifi N
    Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The androgen/androgen receptor axis in prostate cancer.
    Bluemn EG; Nelson PS
    Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
    Bryce A; Ryan CJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?
    Tombal B
    Ann Oncol; 2012 Sep; 23 Suppl 10():x251-8. PubMed ID: 22987972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.